Bachem was founded in 1971 by the entrepreneur Peter Grogg. Over the course of half a century Bachem has become a global leader in the development and production of peptides, important ingredients for a range of vital medicines that treat cancer, diabetes and other diseases.
In 1977, Bachem moved with eight employees to Bubendorf, where the company remains headquartered today. Its portfolio makes Bachem an important supplier to the global pharmaceutical and biotechnology industry.
What started out as a small laboratory has grown into a company that employs over 1,500 people at six locations worldwide. Last year, despite pandemic conditions, Bachem generated over CHF 400 million for the first time and hired 272 new employees. Bachem intends to grow further in the coming years and plans to invest more than CHF 400 million in the expansion of the company over the next five years.The anniversary celebrations for employees, originally planned on site, will be held as a virtual event due to the COVID-19 pandemic.
Peter Grogg, company founder: “Today we celebrate 50 exciting and successful years of company history. Bachem’s success continues to be rooted in the skills and dedication of its employees. I am certain that Bachem has many more exciting and successful years ahead of it.”
Kuno Sommer, Chairman of the Board of Directors: “Bachem’s exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg’s values and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision.”
Thomas Meier, CEO: “Today’s anniversary is a commitment to the next 50 years. We intend and are able to continue to grow independently and profitably. That is why we are continuing to invest in the future of all our sites. In doing so, we will build on our strengths: our company culture and our commitment to high quality, innovation and customer focus.”
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
Bachem celebrates fifty years of company history. From Peter Grogg’s business idea in the 1970s to the world’s leading company in the development and production of peptides and oligonucleotides. A success story based on courage, innovation, quality, partnership, and unique people.